Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).
Scott D. Patterson
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Marc Peeters
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Other Remuneration - Amgen
Salvatore Siena
Consultant or Advisory Role - Amgen; Bayer; Celgene; Genomic Health; Roche; Sanofi
Eric Van Cutsem
Research Funding - Amgen
Yves Humblet
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Jean-Luc Van Laethem
No relevant relationships to disclose
Thierry Andre
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Ying Tian
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Roger Sidhu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Kelly S. Oliner
Employment or Leadership Position - Amgen
Stock Ownership - Amgen